We aimed to investigate the anti-leukemic effect of the novel compounds and the combination therapeutic effect of the novel FLT3 compound with a PARP1 inhibitor in FLT3-ITD+ AML cells. The gene discussed is FLT3; the disease is acute myeloid leukemia.